Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
NCT05694559
Recruiting
To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families to genetic testing and counseling so that they can know their cancer risk and how to decrease it.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, Colorectal Cancer
Register for Updates
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT06053658
Recruiting
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Renal Cell Carcinoma
Register for Updates
Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes
NCT06236607
Recruiting
Minoritized individuals with type 1 diabetes (T1D) have approximately 2% higher average A1c levels and twice the rate of hospitalizations, complications, and mortality as their white counterparts. However, the efficacy trials establishing the benefits of hybrid closed loop (HCL) pump therapy in T1D have been in more socially advantaged and predominantly non-Hispanic white patients. Use of this technology by individuals with T1D from underserved communities remains very low. The investigators pl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/28/2025
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Diabetes Mellitus, Type 1, Diabetes Complications
Register for Updates
A Study of PHN-010 in Patients with Advanced Solid Tumors
NCT06457997
Recruiting
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: AdventHealth, Orlando, Florida +7 locations
Conditions: Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer
Register for Updates
DMID 23-0015; Lassa Fever CVD 1000
NCT06546709
Recruiting
This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen. The antigen will be presented on a genetically modified and attenuated rabies vector expressing both the rabies glycoprotein (GP) antigen and the Lassa GPC. The inactivated chimeric virus is delivered with a toll-like receptor (TLR-4)-activating oil-in-water emulsion adjuvant. Studies using this vaccine administered as a prime-boost series in mice and... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/28/2025
Locations: University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland
Conditions: Lassa Fever
Register for Updates
Preventing Relapse of Problem Behavior Through Behavioral Economics: A Translational Analysis
NCT06651606
Recruiting
The goal of this clinical trial is to compare a novel tactic for mitigating reinstatement compared to the current standard of care approach using a translational-treatment model. The main questions it aims to answer are: 1. how well does progressive ratio training mitigate response-dependent reinstatement compared to the standard of care approach? 2. how well does progressive ratio training mitigate response-independent reinstatement compared to the standard of care approach?
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
02/28/2025
Locations: Auburn University, Auburn, Alabama +1 locations
Conditions: Problem Behavior
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Valley Clinical Trials, Covina, California +36 locations
Conditions: Obesity
Register for Updates
Linking Affective Dynamics in Response to Daily Stress to Peripheral Vascular Function in Working Age Adults
NCT06860724
Recruiting
The objective of this proposal is to determine whether heightened negative affective responsivity (NA-R) to daily stressors is related to blunted nitric oxide (NO)-mediated endothelium-dependent dilation (EDD) in working age adults and the extent to which this association is impacted by major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2025
Locations: University of Delaware, Newark, Delaware
Conditions: Major Depressive Disorder
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Birmingham, Alabama +129 locations
Conditions: Neoplasms
Register for Updates
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
NCT04216732
Recruiting
This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of California San Francisco, San Francisco, California +1 locations
Conditions: Advanced Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Register for Updates
Cardiovascular Analysis of PEM
NCT04740736
Recruiting
The purpose of this study is to examine cardiopulmonary function in Chronic Fatigue Syndrome (CFS) patients and determine how it relates to the common symptom of Post-exertional malaise (PEM). Subjects will complete a maximal exercise test on 2 subsequent days. Total blood volume will be measured prior to each exercise test, and patient with hypovolemia on day 1, will be randomized to either a saline or sham infusion prior to the 2nd exercise test. A total of 80 CFS patients will be enrolled.
Gender:
ALL
Ages:
Between 25 years and 60 years
Trial Updated:
02/28/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Myalgic Encephalomyelitis, Chronic Fatigue Syndrome
Register for Updates
Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy
NCT05115760
Recruiting
This phase II trial studies the effect of a plant-based oral nutrition supplement, Kate Farms Standard 1.4 and/or Standard 1.0. as a primary source of nutrition in reducing the gastrostomy tube placement rate in patients with head and neck cancer that has spread to nearby tissue or lymph nodes (locally advanced) and who are undergoing chemoradiation therapy. Gastrostomy tube (G-tube) placement can be used for enteral feedings and may lead to long term side effects such as swallowing dysfunction... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of California at Los Angeles, Los Angeles, California
Conditions: Locally Advanced Head and Neck Carcinoma
Register for Updates